Metsera, Inc., a company developing next-generation obesity treatments, has entered into an amended merger agreement with Pfizer, accepting Pfizer’s $10 billion acquisition bid. This follows a bidding war with Novo Nordisk and the subsequent withdrawal of its offer. Under the agreement Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash. T...